THE PHYSIOLOGIC EFFECT of nitroglycerin in patients with ischemic heart disease has been a focus of intense clinical investigation. However, some disagreement about the mechanisms by which nitroglycerin relieves myocardial ischemia still exists,' for several reasons. The action of nitroglycerin may vary, depending on the dose or route of administration. Also, parenteral nitroglycerin can be given by bolus or slow infusion into the systemic or coronary circulation. To further complicate the issue, the patient population is not homogeneous. Myocardial ischemia may result from a fixed coronary stenosis that prevents an increase in coronary flow when myocardial oxygen requirements are increased, from coronary artery spasm, or from a combination of spasm and fixed coronary stenosis.
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The preceding article by Brown and colleagues2 focuses on the effect of nitroglycerin on coronary stenosis diameter. These investigators used both sublingual and intracoronary nitroglycerin and made quantitative coronary angiographic measurements of coronary stenoses. In 46 patients, they showed that sublingual nitroglycerin dilates both the coronary stenosis and the adjacent artery. They then administered low-dose intracoronary nitroglycerin by infusion (25 gg/min) to other patients and found similar coronary dilatation and improvement in left ventricular performance in selected patients. None of these latter patients were reported to have coronary artery spasm, yet almost all patients showed dilatation of the coronary stenosis. These observations were interpreted to show that vasodilatation of epicardial coronary stenoses is usually a major component of the beneficial response to nitroglycerin in patients with coronary artery disease.
The observation that nitroglycerin may dilate coronary stenoses agrees with previous results using sublingual nitroglycerin.3 4 However, data in these reports conflict with those of Brown et al., i.e., although many coronary artery stenoses dilate after nitroglycerin, stenoses with the smallest luminal diameter often did not dilate.4 For example, when coronary stenoses were measured, only 14% (two of 14) of those 1.2 mm or smaller dilated at least 0.1 mm after nitroglycerin. In contrast, 59% (16 of 27) of stenoses greater than 1.2 mm dilated an average of 1 1% after nitroglycerin. The stenoses in which the diameter was 1.2 mm or smaller presumably would also be those most likely to limit coronary flow and have the largest pressure gradients across them. What caused these differences is not known. Quantitative angiographic techniques used by Brown et al. differ from those used in the other studies, but reported accuracy (approximately 0.1 mm), resolution and reproducibility of both seem similar.4"8 Perhaps studies in more patients using similar quantitative angiographic techniques will provide more insight about these conflicting observations (i.e., which coronary stenoses enlarge after nitroglycerin).
The data from the intracoronary infusion of nitroglycerin is particularly interesting. Parenteral nitroglycerin is being prepared more frequently by hospital pharmacies and used in hospitalized patients with ischemic heart disease. Probably, preparations for parenteral administration soon will be available commercially, and therefore, data on the effects of parenteral nitroglycerin on the coronary circulation are of immediate clinical relevance.
Brown et al. studied the effect on coronary artery diameter and ventricular performance of a low-dose intracoronary infusion of nitroglycerin in 17 patients with elevated pulmonary capillary wedge pressures. Eleven of these patients were selected because aortic systolic pressure did not change after intracoronary nitroglycerin or, at most, fell by 9 mm Hg. In these patients, nine coronary stenoses averaging 68 ± 9% diameter reduction before nitroglycerin infusion were analyzed. Although stenosis area increased 0.87-1.20 mm2 after the nitroglycerin infusion, the percent reduction of the stenosis did not change because of dilatation in the adjacent vessel. In the 11 patients, left ventricular performance appeared to improve (maintained cardiac output at a reduced filling pressure). Brown et al. hypothesized that their method of intracoronary nitroglycerin administration, i.e., infusion of 50 ,ig over 2-3 minutes, was particularly important in achieving these good results. The proposed mechanism of action requires that these patients with coronary stenoses had ischemic myocardium in the absence of angina and/or ECG changes prior to intracoronary infusion of nitroglycerin. This may be so, but one can question whether stenoses of this severity uniformly produce myocardial ischemia at rest. Furthermore, although left ventricular performance appeared to improve after intracoronary nitroglycerin, right ventricular performance did not change (unchanged filling pressure and stroke volume). A more detailed look at the reported physiologic responses seems important. For example, the reported elevated right atrial pressures (> 10 mm Hg) suggest an important degree of right ventricular dysfunction. This elevation of right ventricular filling pressure is not usually seen EDITORIAL changes in left ventricular performance can be measured with this technique, in contrast to average changes over several seconds, when stroke volume is measured by indicator-dilution or Fick techniques. Changes in regional wall motion in the setting of unchanged systemic hemodynamics would also seem a reasonable approach and could be done using either contrast or radionuclide angiography or two-dimensional echocardiography.
The provocative data presented by Brown and coworkers warrant continued investigation to determine if the direct coronary effect of nitroglycerin is an important mechanism for relief of myocardial ischemia in patients with effort angina. The studies we have proposed might be helpful in clarifying the issue.
